ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q2 2023. The put-call ratio across all filers is 0.63 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $857,438 | -39.6% | 7,997 | -31.2% | 0.01% | -46.7% |
| Q4 2022 | $1,419,517 | -99.9% | 11,623 | -24.0% | 0.02% | -11.8% |
| Q3 2022 | $1,578,949,000 | +110548.1% | 15,291 | -0.4% | 0.02% | +21.4% |
| Q2 2022 | $1,427,000 | -27.7% | 15,349 | -8.8% | 0.01% | -6.7% |
| Q1 2022 | $1,975,000 | -18.3% | 16,825 | -6.3% | 0.02% | +66.7% |
| Q4 2021 | $2,416,000 | – | 17,958 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |